Literature DB >> 22230154

Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial.

Giancarlo Marenzi1, Cristina Ferrari, Ivana Marana, Emilio Assanelli, Monica De Metrio, Giovanni Teruzzi, Fabrizio Veglia, Franco Fabbiocchi, Piero Montorsi, Antonio L Bartorelli.   

Abstract

OBJECTIVES: This study investigated the effect of furosemide-forced diuresis and intravenous saline infusion matched with urine output, using a novel dedicated device designed for contrast-induced nephropathy (CIN) prevention.
BACKGROUND: CIN is a frequent cause of acute kidney injury associated with increased morbidity and mortality.
METHODS: A total of 170 consecutive patients with chronic kidney disease (CKD) undergoing coronary procedures were randomized to either furosemide with matched hydration (FMH group, n = 87) or to standard intravenous isotonic saline hydration (control group; n = 83). The FMH group received an initial 250-ml intravenous bolus of normal saline over 30 min followed by an intravenous bolus (0.5 mg/kg) of furosemide. Hydration infusion rate was automatically adjusted to precisely replace the patient's urine output. When a urine output rate >300 ml/h was obtained, patients underwent the coronary procedure. Matched fluid replacement was maintained during the procedure and for 4 h post-treatment. The definition of CIN was a ≥25% or ≥0.5 mg/dl rise in serum creatinine over baseline.
RESULTS: In the FMH group, no device- or therapy-related complications were observed. Four (4.6%) patients in the FMH group developed CIN versus 15 (18%) controls (p = 0.005). A lower incidence of cumulative in-hospital clinical complications was also observed in FMH-treated patients than in controls (8% vs. 18%; p = 0.052).
CONCLUSIONS: In patients with CKD undergoing coronary procedures, furosemide-induced high urine output with matched hydration significantly reduces the risk of CIN and may be associated with improved in-hospital outcome. (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention [MYTHOS]; NCT00702728).
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230154     DOI: 10.1016/j.jcin.2011.08.017

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  50 in total

Review 1.  Contrast-induced nephropathy in CT: incidence, risk factors and strategies for prevention.

Authors:  Shu Min Tao; Julian L Wichmann; U Joseph Schoepf; Stephen R Fuller; Guang Ming Lu; Long Jiang Zhang
Journal:  Eur Radiol       Date:  2015-12-18       Impact factor: 5.315

2.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2013-08       Impact factor: 2.801

3.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Jpn J Radiol       Date:  2013-08       Impact factor: 2.374

Review 4.  How to balance risks and benefits in the management of CKD patients with coronary artery disease.

Authors:  Giancarlo Marenzi; Nicola Cosentino; Carlo Guastoni
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

Review 5.  Contrast medium induced acute kidney injury: a narrative review.

Authors:  Valentina Pistolesi; Giuseppe Regolisti; Santo Morabito; Ilaria Gandolfini; Silvia Corrado; Giovanni Piotti; Enrico Fiaccadori
Journal:  J Nephrol       Date:  2018-05-25       Impact factor: 3.902

Review 6.  Acute kidney injury: new studies.

Authors:  Antoine G Schneider; Rinaldo Bellomo
Journal:  Intensive Care Med       Date:  2013-02-16       Impact factor: 17.440

7.  Additional furosemide treatment beyond saline hydration for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials.

Authors:  Guoqiang Gu; Ying Zhang; Rui Lu; Wei Cui
Journal:  Int J Clin Exp Med       Date:  2015-01-15

8.  The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization.

Authors:  Xingji Lian; Wenfei He; Huimin Zhan; Jiyan Chen; Ning Tan; Pengcheng He; Yuanhui Liu
Journal:  Int Urol Nephrol       Date:  2019-10-22       Impact factor: 2.370

Review 9.  [Contrast medium-induced acute kidney injury-Consensus paper of the working group "Heart and Kidney" of the German Cardiac Society and the German Society of Nephrology].

Authors:  J Latus; V Schwenger; G Schlieper; H Reinecke; J Hoyer; P B Persson; B A Remppis; F Mahfoud
Journal:  Internist (Berl)       Date:  2020-12-21       Impact factor: 0.743

10.  Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure.

Authors:  Geng Qian; Chang-Fu Liu; Jun Guo; Wei Dong; Jin Wang; Yundai Chen
Journal:  Clin Cardiol       Date:  2019-01-07       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.